EMA Withdrawn: Temozolomide Hexal (temozolomide) — Hexal AG

View source ↗

Summary

Temozolomide Hexal has been withdrawn from the market by Hexal AG in Europe for glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Temozolomide Hexal (temozolomide)

Snippet

Status: Withdrawn. Therapeutic area: Glioma. MAH: Hexal AG. Decision date: 15/09/2022